Synergy Pharmaceuticals Inc.

Novel approach to GI disease

We are developing the first GI platform based on uroguanylin – a naturally occurring human peptide that plays a key role in regulating normal digestive activity.

Learn more about Synergy’s uroguanylin based patform

Leaders in our field

We have an experienced management team with industry expertise and a proven background of execution.

View our management team

Decisions based on data

We make every decision based on real data – it’s what drives the success of our clinical programs and our company.

Read about our clinical trials

Our Approach

Our proprietary GI platform is based on uroguanylin– a naturally occurring human peptide that plays a key role in regulating normal digestive activity. We have discovered and are developing two unique analogs of uroguanylin, plecanatide and dolcanatide (formerly SP-333), as novel therapies for the treatment of GI diseases and disorders.

Learn more about Synergy's Approach

Drug Pipeline

Synergy’s Proprietary Platform

Plecanatide is our first generation uroguanylin analog in late-stage clinical development for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Dolcanatide is our next generation uroguanylin analog that has successfully completed a phase 2 study in patients with opioid induced constipation (OIC) and is currently being evaluated for the treatment of ulcerative colitis (UC).

Learn More about Synergy's Drug Pipeline
Compound Indication Phase 1 Phase 2 Phase 3 Market
Plecanatide
(sp-304)
CIC
IBS-C
DOLCANATIDE
(sp-333)
OIC
UC
Go to News & Media

Latest News & Events

Go To Investor Relations

Investor Relations

Overview

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders.

Recent Documents

SGYP NASDAQ
Volume
Market Cap
Change